Aspect Biosystems is a technology company.
Aspect Biosystems has raised $140.0M across 2 funding rounds.
Aspect Biosystems has raised $140.0M in total across 2 funding rounds.
Aspect Biosystems is a biotechnology company developing a full-stack tissue therapeutic platform that uses proprietary AI-powered bioprinting to create implantable bioprinted tissue therapeutics (BTTs). These BTTs replace, repair, or supplement lost biological functions, targeting metabolic and endocrine diseases like type 1 diabetes, primary adrenal insufficiency, and acute liver failure.[1][2][3][4][8] The platform serves patients with incurable diseases and partners with pharma giants like Novo Nordisk, addressing root causes without chronic immunosuppression or full organ transplants.[1][3][6] Growth momentum includes a major 2023 partnership with Novo Nordisk—yielding $75M upfront and up to $650M in milestones—plus investments from Radical Ventures and Dimension Capital, advancing an internal pipeline from preclinical stages.[1][5][6]
Aspect Biosystems spun out from engineering and medicine research groups at the University of British Columbia, evolving from initial 3D bioprinting for drug testing models into a comprehensive regenerative medicine platform.[7] Founders leveraged expertise in microfluidics and tissue engineering to pioneer on-demand human tissue creation, starting with customizable 3D models for pharma research before shifting to therapeutics.[5][7] Early traction came from partnerships with academic and biopharma entities, culminating in high-profile deals like Novo Nordisk for diabetes and obesity treatments, marking a pivot to clinical-stage products.[1][3][6][7]
Aspect's platform stands out through integrated, end-to-end capabilities beyond basic bioprinting:
Aspect rides the regenerative medicine wave, merging bioprinting, AI, and stem cells to pioneer BTTs amid rising demand for cell therapies beyond traditional transplants.[1][2][7] Timing aligns with advances in stem cell differentiation and biomanufacturing, fueled by pharma's push for functional cures in chronic diseases affecting millions (e.g., diabetes).[3][6] Market forces like Novo Nordisk's scale and investor interest from Radical Ventures favor Aspect, enabling rapid clinic progression while reducing organ shortage risks.[1][5][6] It influences the ecosystem by enabling precise drug testing models and novel therapeutics, potentially reshaping personalized medicine and accelerating shelved drug revivals.[7]
Aspect is poised to advance its preclinical pipeline into clinical trials, prioritizing diabetes/obesity via Novo Nordisk and internal programs for liver/adrenal disorders, with potential first-in-human data soon.[6][8] Trends like AI-optimized biomanufacturing and allogeneic cell therapies will amplify its edge, expanding to more endocrine indications amid growing regenerative investment.[1][4][5] Its influence may evolve from platform innovator to category leader, transforming incurable disease treatment—building on its UBC roots to deliver the functional cures that redefine biotech.
Aspect Biosystems has raised $140.0M in total across 2 funding rounds.
Aspect Biosystems's investors include Kevin Hartz, Accel, Dimension Capital, Felicis Ventures, Sequoia Capital, Brightspark Ventures, Freestyle Capital, FTX Ventures, Jump Crypto.
Aspect Biosystems has raised $140.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $120.0M Series B | Kevin Hartz, Accel, Dimension Capital, Felicis Ventures, Sequoia Capital | |
| Jan 1, 2020 | $20.0M Series A | Brightspark Ventures, Freestyle Capital, FTX Ventures, Jump Crypto |